Search Results
Sep 01, 2026, 07:55 ET Hornbeck and Helix Complete Merger, Creating a Premier Integrated Offshore Services Company
HOUSTON and COVINGTON, La., Sept. 1, 2026 /PRNewswire/ -- Helix Energy Solutions Group, Inc. ("Helix") (NYSE: HLX) and Hornbeck Offshore Services, Inc. ("Hornbeck") today announced they have completed the previously announced combination in an all-stock transaction,
More news about: Hornbeck Offshore Services, Inc.
Aug 27, 2026, 07:02 ET Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
mix continues to improve. Henlius' HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and two HLX14 (denosumab injection) products were approved and commercially launched in Canada. To date, Henlius has 10 products approved
More news about: Fosun
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
has been accepted.Lead pipeline candidates HLX43 and HLX22 are progressing in international multi-center trials across China, the US, Europe, Australia, Japan and other geographies. As a potential best-in-class pan-tumor PD-L1-targeting ADC, HLX43 has demonstrated promising preliminary clinical
More news about: Fosun Pharma
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
breast cancer pipeline including lasofoxifene (HLX78), a novel endocrine therapy; dulpatatug* (HLX22), a novel-epitope monoclonal antibody (mAb) targeting HER2; HLX87, a HER2-targeted ADC; HLX97, an oral KAT6A/B inhibitor; HLX49, a HER2 biparatopic ADC; and HLX319, the first Chinese-developed fixed-dose subcutaneous
More news about: Henlius
Aug 21, 2026, 08:37 ET 復宏漢霖2026年中期業績：盈利能力持續躍升，進入全球價值兌現期
完成首例患者入組；其用於治療HER2低表達乳腺癌的II期研究、聯合HER2 ADC HLX87一線治療HER2陽性乳腺癌的II/III期研究亦持續推進中。Pimurutamab 聯合漢斯狀®及化療一線治療晚期sqNSCLC的II/III期臨床試驗已通過澳大利亞藥品管理局的臨床試驗備案並完成中國首例患者給藥。與此同時，公司高效推進以HLX3901（DLL3 x DLL3 x CD3 x CD28四抗TCE）、HLX3902（STEAP1 x CD3 x CD28三抗TCE）、HLX48（c-MET x EGFR雙抗ADC）、HLX97（KAT6A/B小分子抑制劑）及HLX316（B
More news about: 復宏漢霖
Aug 17, 2026, 21:16 ET Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-dsgr-hlx-atai-crnx-obtaining-fair-deals-for-their-shareholders-302853324.htmlSOURCE
More news about: Halper Sadeh LLP
Aug 17, 2026, 06:44 ET HenliusとSandoz、バイオシミラー・プラットフォームのグローバルな価値を最大限に引き出すための戦略的提携を締結
、グローバル供給プラットフォームの価値をさらに引き出しています。HLX05-NについてHLX05-Nは、Henliusが独自に開発したセツキシマブ注射剤のバイオシミラーであり、転移性大腸がんおよび頭頸部扁平上皮がんの治療を目的としています。2026年7月、中国において、Henliusが独自に開発したセツキシマブ注射剤のバイオシミラー「HLX05-N」について、転移性大腸がん（mCRC）患者を対象とした第1相臨床試験において、最初の患者への投与が開始されました。IQVIA MIDAS™ （IQVIAは、製薬・ヘルスケア業界における専門情報および戦略的コ
More news about: Henlius
Aug 17, 2026, 00:08 ET Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
to unlock the global commercial value of the partnered products.The initial assets covered under the agreement include HLX05-N, a proposed cetuximab biosimilar; HLX16, a proposed evolocumab biosimilar; and a proposed belimumab biosimilar. In addition, Sandoz has obtained an option for HLXTE-HAase1001,
More news about: Henlius
Aug 17, 2026, 00:00 ET 復宏漢霖與山德士達成戰略合作，加速釋放生物類似藥全球價值
05-NHLX05-N是本公司自主研發的西妥昔單抗注射液生物類似藥，擬用於轉移性結直腸癌及頭頸部鱗狀細胞癌的治療。2026年7月，HLX05-N在轉移性結直腸癌(mCRC)患者中的臨床I期研究於中國完成首例患者給藥。根據IQVIA MIDASTM，2025年度，西妥昔單抗注射液全球銷售額約為16.96億美元。關於HLX16HLX16是復宏漢霖自主開發的依洛尤單抗生物類似藥，擬用於治療原發性高膽固醇血症（包括雜合子型家族性和非家族性），目前該產品處於臨床前研究階段。根據IQVIA MIDASTM
More news about: 復宏漢霖
Aug 06, 2026, 00:51 ET Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
has been approved for marketing in over 40 countries and regions. HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, and other indications. HLX22 is the world's first anti-HER2-targeted therapy to receive Orphan
More news about: Fosun
Jul 02, 2026, 00:12 ET Fosun International Garners Five Awards from Corporate Governance Asia
has developed anticancer and antimalarial drugs that have widely benefited cancer patients and severe malaria patients. Among them, HANSIZHUANG, HLX43, HLX22, and other marketed and pipeline innovative drugs have delivered several "world's first" breakthroughs. HANSIZHUANG became the world's first monoclonal
More news about: Fosun
Jul 02, 2026, 00:04 ET 復星國際獲《亞洲企業管治》五大獎項
創新驅動，積極回饋社會復星堅持創新驅動，旗下健康板塊研發的抗癌、抗瘧藥物，廣泛惠及癌症患者及重症瘧疾患者。其中，漢斯狀、HLX43、HLX22等上市及在研創新藥實現多項「全球首個」突破。漢斯狀®成為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗，已在40餘國家和地區上市；HLX43在非小細胞肺癌、婦科腫瘤、食管鱗癌等多個領域展現「高效、低毒」優勢；HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。截至2025年12月底，復星醫藥自主研發的注射用青蒿琥酯累計救治全球超8,800萬重症瘧疾患者，已向全球累計供應超過4.4億支注射用青蒿琥酯。
More news about: 復星
Jun 09, 2026, 13:21 ET Are NATH, HLX, AIRI, OMEX Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-nath-hlx-airi-omex-obtaining-fair-deals-for-their-shareholders-302795511.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 02, 2026, 11:05 ET Breaking Barreras: HACE's 44th National Summit Empowers the Next Generation of Latino Leaders
2026 Alumni Icon AwardDiane Garza — 2026 Coach Catalyst AwardExperian — 2026 Corporate Champion AwardHispanic/Latinx BRG (HLX BRG) — 2026 ERG of the YearMuñeca Torres-Rivera — 2026 Mujer Maravilla AwardKrizel Rodriguez — 2026 Redefining Leader AwardAndrés
More news about: Hispanic Alliance for Career Enhancement (HACE)
May 27, 2026, 05:38 ET Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
successfully selected for a Rapid Oral Presentation, providing a new, efficient treatment option for adult patients with NF1-PN.Furthermore, Henlius' HLX43, a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, will have its key subgroup progression-free survival (PFS) data in non-small cell lung
More news about: Fosun
May 06, 2026, 14:27 ET SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX
HLX) related to its merger with Hornbeck Offshore Services, Inc. Upon completion of the proposed transaction, Helix shareholders will own approximately
More news about: Monteverde & Associates PC
Apr 29, 2026, 10:00 ET European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity
More news about: Henlius
Apr 29, 2026, 06:09 ET 復宏漢霖與Organon共同宣佈歐洲首個帕妥珠單抗生物類似藥POHERDY®獲歐盟委員會批准
漢斯狀®（斯魯利單抗，歐洲商品名：Hetronifly®）作為全球首個獲批一線治療小細胞肺癌的抗PD-1單抗，正加速全球佈局，已在全球40餘個市場獲批上市；同時，多款潛力創新資產，包括PD-L1 ADC HLX43及新表位HER2單抗HLX22正全面推進全球關鍵性臨床研究。依托通過中、歐、美三地GMP認證的生產體系，復宏漢霖已建成總產能達84,000升的生物藥生產平台，形成覆蓋全球六大洲的穩定供應網絡。未來，復宏漢霖將始終堅持以患者為中心，聚焦未滿足的臨床需求，持續推動創新成果向臨床價值與患者可及轉化，在全球生物醫藥創新生態中創造長期而穩健的價值。關於OrganonOrganon（紐約證券交易所代碼：OGN）是一
More news about: 復宏漢霖
Apr 28, 2026, 10:54 ET Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
trials for the first-line treatment of HER2-positive recurrent or metastatic breast cancer in combination with HLX87. HLX43 (PD-L1 ADC) in combination with HLX07 or serplulimab injection, and HLX701 (CD47 fusion protein), among others, have entered Phase I clinical trials, further enhancing the Company's
More news about: Fosun Pharma
Apr 28, 2026, 10:38 ET 復星國際：創造可持續影響 發佈2025年ESG報告及氣候信息披露報告
期競爭力的產品管線與綜合解決方案。同時，持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術。其中，漢斯狀、HLX43、HLX22等上市及在研創新藥實現多項「全球首個」突破。漢斯狀®成為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗，已在40餘國家和地區上市；HLX43在非小細胞肺癌、婦科腫瘤、食管鱗癌等多個領域展現「高效、低毒」優勢；HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。此外，復星醫藥持續助力非洲社區健康發展。截至2025年12月底，復星醫藥自主研發的注射用青蒿琥酯累計救治全球超8,800萬重症
More news about: 復星
Apr 28, 2026, 10:36 ET Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report
Additionally, it actively advances cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids.Among them, HANSIZHUANG, HLX43, HLX22, and other marketed and pipeline innovative drugs have delivered several "world's first" breakthroughs. HANSIZHUANG became the world's first monoclonal
More news about: Fosun
Apr 23, 2026, 18:51 ET Are TRBG, HLX, LPSN Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-trbg-hlx-lpsn-obtaining-fair-deals-for-their-shareholders-302752337.htmlSOURCE
More news about: Halper Sadeh LLP
Mar 24, 2026, 10:47 ET Fosun Pharma Announces 2025 Annual Results
anti-PD-1 monoclonal antibody to receive such approval in the EU and accelerating the company's globalization pace; antibody and ADC drugs such as HLX43 and HLX22 entered key clinical phases, continuously improving the echelon of the oncology pipeline. The marketing application for the second CAR-T product
More news about: Fosun Pharma
Mar 22, 2026, 22:20 ET Henlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios
del informe. Por otro lado, Henlius continúa impulsando su cartera de productos innovadores, con activos clave como dulpatatug (HLX22, un nuevo epítopo anti-HER2 mAb) y HLX43 (PD-L1 ADC) que se encuentran en fases clínicas críticas.Gracias a sus capacidades integradas que abarcan I+D, operaciones
More news about: Henlius
Mar 22, 2026, 22:18 ET Henlius présente ses résultats pour 2025 : croissance soutenue du chiffre d'affaires et du bénéfice, progression de la validation de l'innovation et des opérations mondiales
considérée. Entre-temps, Henlius continue de faire progresser son pipeline d'innovations, avec des actifs clés tels que dulpatatug (HLX22, nouvel épitope anti-HER2 mAb) et HLX43 (PD-L1 ADC) qui entrent dans des phases cliniques critiques.Grâce à ses capacités intégrées en matière de R&D, d'opérations
More news about: Henlius